Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer
CUB-domain containing protein 1 (CDCP1) is a cancer associated cell surface protein that amplifies pro-tumorigenic signalling by other receptors including EGFR and HER2. Its potential as a cancer target is supported by studies showing that anti-CDCP1 antibodies inhibit cell migration and survival ,...
Saved in:
| Published in | Theranostics Vol. 10; no. 5; pp. 2095 - 2114 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Australia
Ivyspring International Publisher Pty Ltd
01.01.2020
Ivyspring International Publisher |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | CUB-domain containing protein 1 (CDCP1) is a cancer associated cell surface protein that amplifies pro-tumorigenic signalling by other receptors including EGFR and HER2. Its potential as a cancer target is supported by studies showing that anti-CDCP1 antibodies inhibit cell migration and survival
, and tumor growth and metastasis
. Here we characterize two anti-CDCP1 antibodies, focusing on immuno-conjugates of one of these as a tool to detect and inhibit ovarian cancer.
: A panel of ovarian cancer cell lines was examined for cell surface expression of CDCP1 and loss of expression induced by anti-CDCP1 antibodies 10D7 and 41-2 using flow cytometry and Western blot analysis. Surface plasmon resonance analysis and examination of truncation mutants was used to analyse the binding properties of the antibodies for CDCP1. Live-cell spinning-disk confocal microscopy of GFP-tagged CDCP1 was used to track internalization and intracellular trafficking of CDCP1/antibody complexes.
, zirconium 89-labelled 10D7 was detected by positron-emission tomography imaging, of an ovarian cancer patient-derived xenograft grown intraperitoneally in mice. The efficacy of cytotoxin-conjugated 10D7 was examined against ovarian cancer cells
and
.
: Our data indicate that each antibody binds with high affinity to the extracellular domain of CDCP1 causing rapid internalization of the receptor/antibody complex and degradation of CDCP1 via processes mediated by the kinase Src. Highlighting the potential clinical utility of CDCP1, positron-emission tomography imaging, using zirconium 89-labelled 10D7, was able to detect subcutaneous and intraperitoneal xenograft ovarian cancers in mice, including small (diameter <3 mm) tumor deposits of an ovarian cancer patient-derived xenograft grown intraperitoneally in mice. Furthermore, cytotoxin-conjugated 10D7 was effective at inhibiting growth of CDCP1-expressing ovarian cancer cells
and
.
: These data demonstrate that CDCP1 internalizing antibodies have potential for killing and detection of CDCP1 expressing ovarian cancer cells. |
|---|---|
| AbstractList | CUB-domain containing protein 1 (CDCP1) is a cancer associated cell surface protein that amplifies pro-tumorigenic signalling by other receptors including EGFR and HER2. Its potential as a cancer target is supported by studies showing that anti-CDCP1 antibodies inhibit cell migration and survival
, and tumor growth and metastasis
. Here we characterize two anti-CDCP1 antibodies, focusing on immuno-conjugates of one of these as a tool to detect and inhibit ovarian cancer.
: A panel of ovarian cancer cell lines was examined for cell surface expression of CDCP1 and loss of expression induced by anti-CDCP1 antibodies 10D7 and 41-2 using flow cytometry and Western blot analysis. Surface plasmon resonance analysis and examination of truncation mutants was used to analyse the binding properties of the antibodies for CDCP1. Live-cell spinning-disk confocal microscopy of GFP-tagged CDCP1 was used to track internalization and intracellular trafficking of CDCP1/antibody complexes.
, zirconium 89-labelled 10D7 was detected by positron-emission tomography imaging, of an ovarian cancer patient-derived xenograft grown intraperitoneally in mice. The efficacy of cytotoxin-conjugated 10D7 was examined against ovarian cancer cells
and
.
: Our data indicate that each antibody binds with high affinity to the extracellular domain of CDCP1 causing rapid internalization of the receptor/antibody complex and degradation of CDCP1 via processes mediated by the kinase Src. Highlighting the potential clinical utility of CDCP1, positron-emission tomography imaging, using zirconium 89-labelled 10D7, was able to detect subcutaneous and intraperitoneal xenograft ovarian cancers in mice, including small (diameter <3 mm) tumor deposits of an ovarian cancer patient-derived xenograft grown intraperitoneally in mice. Furthermore, cytotoxin-conjugated 10D7 was effective at inhibiting growth of CDCP1-expressing ovarian cancer cells
and
.
: These data demonstrate that CDCP1 internalizing antibodies have potential for killing and detection of CDCP1 expressing ovarian cancer cells. CUB-domain containing protein 1 (CDCP1) is a cancer associated cell surface protein that amplifies pro-tumorigenic signalling by other receptors including EGFR and HER2. Its potential as a cancer target is supported by studies showing that anti-CDCP1 antibodies inhibit cell migration and survival in vitro , and tumor growth and metastasis in vivo . Here we characterize two anti-CDCP1 antibodies, focusing on immuno-conjugates of one of these as a tool to detect and inhibit ovarian cancer. Methods : A panel of ovarian cancer cell lines was examined for cell surface expression of CDCP1 and loss of expression induced by anti-CDCP1 antibodies 10D7 and 41-2 using flow cytometry and Western blot analysis. Surface plasmon resonance analysis and examination of truncation mutants was used to analyse the binding properties of the antibodies for CDCP1. Live-cell spinning-disk confocal microscopy of GFP-tagged CDCP1 was used to track internalization and intracellular trafficking of CDCP1/antibody complexes. In vivo , zirconium 89-labelled 10D7 was detected by positron-emission tomography imaging, of an ovarian cancer patient-derived xenograft grown intraperitoneally in mice. The efficacy of cytotoxin-conjugated 10D7 was examined against ovarian cancer cells in vitro and in vivo . Results : Our data indicate that each antibody binds with high affinity to the extracellular domain of CDCP1 causing rapid internalization of the receptor/antibody complex and degradation of CDCP1 via processes mediated by the kinase Src. Highlighting the potential clinical utility of CDCP1, positron-emission tomography imaging, using zirconium 89-labelled 10D7, was able to detect subcutaneous and intraperitoneal xenograft ovarian cancers in mice, including small (diameter <3 mm) tumor deposits of an ovarian cancer patient-derived xenograft grown intraperitoneally in mice. Furthermore, cytotoxin-conjugated 10D7 was effective at inhibiting growth of CDCP1-expressing ovarian cancer cells in vitro and in vivo . Conclusions : These data demonstrate that CDCP1 internalizing antibodies have potential for killing and detection of CDCP1 expressing ovarian cancer cells. CUB-domain containing protein 1 (CDCP1) is a cancer associated cell surface protein that amplifies pro-tumorigenic signalling by other receptors including EGFR and HER2. Its potential as a cancer target is supported by studies showing that anti-CDCP1 antibodies inhibit cell migration and survival in vitro, and tumor growth and metastasis in vivo. Here we characterize two anti-CDCP1 antibodies, focusing on immuno-conjugates of one of these as a tool to detect and inhibit ovarian cancer. Methods: A panel of ovarian cancer cell lines was examined for cell surface expression of CDCP1 and loss of expression induced by anti-CDCP1 antibodies 10D7 and 41-2 using flow cytometry and Western blot analysis. Surface plasmon resonance analysis and examination of truncation mutants was used to analyse the binding properties of the antibodies for CDCP1. Live-cell spinning-disk confocal microscopy of GFP-tagged CDCP1 was used to track internalization and intracellular trafficking of CDCP1/antibody complexes. In vivo, zirconium 89-labelled 10D7 was detected by positron-emission tomography imaging, of an ovarian cancer patient-derived xenograft grown intraperitoneally in mice. The efficacy of cytotoxin-conjugated 10D7 was examined against ovarian cancer cells in vitro and in vivo. Results: Our data indicate that each antibody binds with high affinity to the extracellular domain of CDCP1 causing rapid internalization of the receptor/antibody complex and degradation of CDCP1 via processes mediated by the kinase Src. Highlighting the potential clinical utility of CDCP1, positron-emission tomography imaging, using zirconium 89-labelled 10D7, was able to detect subcutaneous and intraperitoneal xenograft ovarian cancers in mice, including small (diameter < 3 mm) tumor deposits of an ovarian cancer patient-derived xenograft grown intraperitoneally in mice. Furthermore, cytotoxin-conjugated 10D7 was effective at inhibiting growth of CDCP1-expressing ovarian cancer cells in vitro and in vivo. Conclusions: These data demonstrate that CDCP1 internalizing antibodies have potential for killing and detection of CDCP1 expressing ovarian cancer cells. |
| Author | Arachchige, Buddhika J Perrin, Lewis C He, Yaowu Puttick, Simon Stehbens, Samantha J Conroy, Paul J Haluska, Paul Whisstock, James C Weroha, S John Pollock, Pamela M Harrington, Brittney S Kryza, Thomas Law, Ruby H P Khan, Tashbib Robbins, Katherine K Reed, Sarah Lourie, Rohan Cuda, Tahleesa Sokolowski, Kamil A Tse, Brian Wc Salomon, Carlos Hooper, John D |
| AuthorAffiliation | 5 Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC 3800, Australia 3 Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Australia 6 Preclinical Imaging Facility, Translational Research Institute, Woolloongabba, QLD 4102, Australia 4 Commonwealth Scientific and Industrial Research Organisation, Probing Biosystems Future Science Platform, Herston, QLD 4029, Australia 11 Mater Health Services, South Brisbane, QLD 4101, Australia 7 Centre for Clinical Research, University of Queensland, Herston, Qld 4029, Australia 8 Institute of Health and Biomedical Innovation, Queensland University of Technology, Woolloongabba, QLD 4102, Australia 2 Mater Ovarian Cancer Research Collaborative, Mater Adult Hospital, South Brisbane, QLD 4101, Australia 1 Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia 9 Department of Me |
| AuthorAffiliation_xml | – name: 2 Mater Ovarian Cancer Research Collaborative, Mater Adult Hospital, South Brisbane, QLD 4101, Australia – name: 8 Institute of Health and Biomedical Innovation, Queensland University of Technology, Woolloongabba, QLD 4102, Australia – name: 4 Commonwealth Scientific and Industrial Research Organisation, Probing Biosystems Future Science Platform, Herston, QLD 4029, Australia – name: 11 Mater Health Services, South Brisbane, QLD 4101, Australia – name: 6 Preclinical Imaging Facility, Translational Research Institute, Woolloongabba, QLD 4102, Australia – name: 5 Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC 3800, Australia – name: 1 Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia – name: 3 Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Australia – name: 9 Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA – name: 7 Centre for Clinical Research, University of Queensland, Herston, Qld 4029, Australia – name: 10 Merck Research Laboratories, Rahway, NJ, USA |
| Author_xml | – sequence: 1 givenname: Brittney S surname: Harrington fullname: Harrington, Brittney S organization: Mater Ovarian Cancer Research Collaborative, Mater Adult Hospital, South Brisbane, QLD 4101, Australia – sequence: 2 givenname: Yaowu surname: He fullname: He, Yaowu organization: Mater Ovarian Cancer Research Collaborative, Mater Adult Hospital, South Brisbane, QLD 4101, Australia – sequence: 3 givenname: Tashbib surname: Khan fullname: Khan, Tashbib organization: Mater Ovarian Cancer Research Collaborative, Mater Adult Hospital, South Brisbane, QLD 4101, Australia – sequence: 4 givenname: Simon surname: Puttick fullname: Puttick, Simon organization: Commonwealth Scientific and Industrial Research Organisation, Probing Biosystems Future Science Platform, Herston, QLD 4029, Australia – sequence: 5 givenname: Paul J surname: Conroy fullname: Conroy, Paul J organization: Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC 3800, Australia – sequence: 6 givenname: Thomas surname: Kryza fullname: Kryza, Thomas organization: Mater Ovarian Cancer Research Collaborative, Mater Adult Hospital, South Brisbane, QLD 4101, Australia – sequence: 7 givenname: Tahleesa surname: Cuda fullname: Cuda, Tahleesa organization: Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia – sequence: 8 givenname: Kamil A surname: Sokolowski fullname: Sokolowski, Kamil A organization: Preclinical Imaging Facility, Translational Research Institute, Woolloongabba, QLD 4102, Australia – sequence: 9 givenname: Brian Wc surname: Tse fullname: Tse, Brian Wc organization: Preclinical Imaging Facility, Translational Research Institute, Woolloongabba, QLD 4102, Australia – sequence: 10 givenname: Katherine K surname: Robbins fullname: Robbins, Katherine K organization: Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia – sequence: 11 givenname: Buddhika J surname: Arachchige fullname: Arachchige, Buddhika J organization: Centre for Clinical Research, University of Queensland, Herston, Qld 4029, Australia – sequence: 12 givenname: Samantha J surname: Stehbens fullname: Stehbens, Samantha J organization: Institute of Health and Biomedical Innovation, Queensland University of Technology, Woolloongabba, QLD 4102, Australia – sequence: 13 givenname: Pamela M surname: Pollock fullname: Pollock, Pamela M organization: Institute of Health and Biomedical Innovation, Queensland University of Technology, Woolloongabba, QLD 4102, Australia – sequence: 14 givenname: Sarah surname: Reed fullname: Reed, Sarah organization: Centre for Clinical Research, University of Queensland, Herston, Qld 4029, Australia – sequence: 15 givenname: S John surname: Weroha fullname: Weroha, S John organization: Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA – sequence: 16 givenname: Paul surname: Haluska fullname: Haluska, Paul organization: Merck Research Laboratories, Rahway, NJ, USA – sequence: 17 givenname: Carlos surname: Salomon fullname: Salomon, Carlos organization: Centre for Clinical Research, University of Queensland, Herston, Qld 4029, Australia – sequence: 18 givenname: Rohan surname: Lourie fullname: Lourie, Rohan organization: Mater Health Services, South Brisbane, QLD 4101, Australia – sequence: 19 givenname: Lewis C surname: Perrin fullname: Perrin, Lewis C organization: Mater Health Services, South Brisbane, QLD 4101, Australia – sequence: 20 givenname: Ruby H P surname: Law fullname: Law, Ruby H P organization: Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC 3800, Australia – sequence: 21 givenname: James C surname: Whisstock fullname: Whisstock, James C organization: Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC 3800, Australia – sequence: 22 givenname: John D surname: Hooper fullname: Hooper, John D organization: Mater Ovarian Cancer Research Collaborative, Mater Adult Hospital, South Brisbane, QLD 4101, Australia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32104500$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkFtLAzEQhYNUbK198QfIgm_C1mRz2c2LUNYrFvRBn0OaTdqUblKz2YL_3u1FqfMyM8zhzOE7Bz3nnQbgEsFxjii8jQvnxxjmmJ2AASpwkeaMwN7R3AejplnCrgjMOOJnoI8zBAmFcABeJy7atLwv31Fi67p1PlXeLdu5jLpJjA9JpaNW0XqXSFcl1i3szO5WbxK_kcFKlyjplA4X4NTIVaNHhz4En48PH-VzOn17eikn01QRyGJKs8owThHLiSmgIYbmWGqEZd6FUlVmNNMES65INZOMKIwwN7TCUDGlUEHwENztfdftrNaV0i4GuRLrYGsZvoWXVvy_OLsQc78ROUQcUdQZXB8Mgv9qdRPF0rfBdZlFRnmRUQoJ71Q3e5UKvmmCNn8fEBRb9mLLXuzYd-Kr40x_0l_S-Ae16IGA |
| CitedBy_id | crossref_primary_10_1093_hmg_ddab031 crossref_primary_10_1016_j_lfs_2022_120600 crossref_primary_10_3390_cancers15194839 crossref_primary_10_3389_fmed_2022_1026521 crossref_primary_10_1158_1078_0432_CCR_21_3858 crossref_primary_10_3390_cancers12040869 crossref_primary_10_1038_s41589_021_00783_w crossref_primary_10_1155_2021_3153278 crossref_primary_10_1139_bcb_2020_0227 crossref_primary_10_1158_0008_5472_CAN_20_2978 crossref_primary_10_1021_acs_molpharmaceut_1c00401 crossref_primary_10_3390_ijms22126413 crossref_primary_10_1002_1878_0261_13429 |
| ContentType | Journal Article |
| Copyright | The author(s). 2020. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The author(s) 2020 |
| Copyright_xml | – notice: The author(s). – notice: 2020. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The author(s) 2020 |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PIMPY PQEST PQQKQ PQUKI PRINS 5PM |
| DOI | 10.7150/thno.30736 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Central (Alumni) |
| DatabaseTitleList | MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: ProQuest Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Engineering |
| EISSN | 1838-7640 |
| EndPage | 2114 |
| ExternalDocumentID | 10_7150_thno_30736 32104500 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- 53G 5VS 7X7 8FI 8FJ ABUWG ADBBV ADRAZ AENEX AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BENPR CCPQU CGR CUY CVF DIK ECM EIF FYUFA GROUPED_DOAJ HMCUK HYE KQ8 M48 M~E NPM O5R O5S OK1 PGMZT PIMPY RPM UKHRP AAYXX CITATION 3V. 7XB 8FK AZQEC DWQXO K9. PQEST PQQKQ PQUKI PRINS 5PM |
| ID | FETCH-LOGICAL-c406t-52df6951674f80f4f573ae13a7104cd2fe6e43a9c4dba64c3139f5d30c6cc1843 |
| IEDL.DBID | RPM |
| ISSN | 1838-7640 |
| IngestDate | Tue Sep 17 21:00:07 EDT 2024 Thu Oct 10 18:42:02 EDT 2024 Fri Aug 23 00:48:24 EDT 2024 Sat Sep 28 08:22:59 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | immuno-conjugate CDCP1 antibody ovarian cancer |
| Language | English |
| License | The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c406t-52df6951674f80f4f573ae13a7104cd2fe6e43a9c4dba64c3139f5d30c6cc1843 |
| Notes | Competing Interests: The authors have declared that no competing interest exists. |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019151/ |
| PMID | 32104500 |
| PQID | 2598255049 |
| PQPubID | 5263173 |
| PageCount | 20 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7019151 proquest_journals_2598255049 crossref_primary_10_7150_thno_30736 pubmed_primary_32104500 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-01-01 |
| PublicationDateYYYYMMDD | 2020-01-01 |
| PublicationDate_xml | – month: 01 year: 2020 text: 2020-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Australia |
| PublicationPlace_xml | – name: Australia – name: Wyoming – name: Sydney |
| PublicationTitle | Theranostics |
| PublicationTitleAlternate | Theranostics |
| PublicationYear | 2020 |
| Publisher | Ivyspring International Publisher Pty Ltd Ivyspring International Publisher |
| Publisher_xml | – name: Ivyspring International Publisher Pty Ltd – name: Ivyspring International Publisher |
| SSID | ssj0000402919 |
| Score | 2.3656497 |
| Snippet | CUB-domain containing protein 1 (CDCP1) is a cancer associated cell surface protein that amplifies pro-tumorigenic signalling by other receptors including EGFR... |
| SourceID | pubmedcentral proquest crossref pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | 2095 |
| SubjectTerms | Animals Antibodies Antigens, Neoplasm - immunology Cancer therapies Cell adhesion & migration Cell Adhesion Molecules - antagonists & inhibitors Cell Adhesion Molecules - immunology Cell Line, Tumor Cell Membrane - metabolism Cell Movement - immunology Chemotherapy Female Flow cytometry Immunoconjugates - immunology Kinases Medical prognosis Membrane Proteins - metabolism Metastasis Mice Models, Animal Ovarian cancer Ovarian Neoplasms - metabolism Phosphorylation Positron-Emission Tomography - methods Proteins Radioisotopes - chemistry Radioisotopes - metabolism Research Paper Signal transduction src-Family Kinases - metabolism Surface Plasmon Resonance - methods Transplantation, Heterologous - methods Zirconium - chemistry Zirconium - metabolism |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV09T8MwELWgLDAgvgkUZAlW0yZx7GRCVaGqQCAGKnWLHDtWw-CUNuX3c3bS0oLEmkSO9O7ie3c5v0PoNqA67ipfk0xxTiiXmsQipMTnsWTASMLAJYovr2w4ok_jaNwU3OZNW-VyT3QbtSqlrZF3Aqs0B3SaJvfTT2KnRtm_q80IjW204wcQysGf-ZivaizgoEHiJ7UqKQfq06kmpryzbs0249Afcvm7R3It6AwO0H7DFnGvNu8h2srNEdpb0xA8Rs89UxWk_9B_83FhD3uUBFLcj4Utj80xUFKs8sr1WxksjMKFmRSZ69PCpcblF-TKwmBpjT87QaPB43t_SJoJCURCIK4gi1SaAUdi3EKuqY54KHI_FMAbqFSBzllOQ5FIqjLBqAyB7-lIhV3JpLSTXk5Ry5QmP0c4UzJOaEy1yhisQ7MILgiIXRH3hRLcQzdLvNJpLYSRQgJhUU0tqqlD1UPtJZRp8zHM0x_TeeisRnW1hD1CRKNu10N8A-_VA1b-evOOKSZOBtsKyQNfufj_lZdoN7ApsquatFGrmi3yK-ARVXbtnOUb-qvKHA priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1LS8NAEB58gOhBfFtfLOg1tUk2u8lJpFpEUTxY6C1sdrM0IhutUfTfO5M2Uqte89jDN5PM9y2z3wCcBNzGHeNbLzNSelxq68Uq5J4vYy2QkYRBLRRv78RVn18PosEcNPM7JwC-_intaJ5Uf_TU_nj5PMMPHvlrWyKfOa2GrmxTrop5WAywIlJr1-2E5td_ZBRJiZ-M3UlnXlmGJTrGwiM64zZdmn7xzdm2yak61FuD1QmBZOfjiK_DXO42YGXKVnATbs5dVXjdi-69zwo6_1F6qHof32jH7JUhS2Umr-oWLMeUM6xwwyKrW7dYaVn5jvJZOaYpH0Zb0O9dPnSvvMnQBE9jba5QWBorkDYJSVGw3EYyVLkfKqQSXJvA5iLnoUo0N5kSXIdIAW1kwo4WWtPwl21YcKXLd4FlRscJj7k1mcB1eBbhBYXlLJK-Mkq24LjBK30ee2OkqCkI4JQATmuAW3DQQJk24U0D8g1EccSTFuyMUf1eoglHC-QPvL8fIEfsn3dcMaydsclbHinM3r9r7sNyQIKZ9mf5ASxUo7f8EFlFlR3VKfMFntLMFA priority: 102 providerName: Scholars Portal |
| Title | Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32104500 https://www.proquest.com/docview/2598255049 https://pubmed.ncbi.nlm.nih.gov/PMC7019151 |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3PT8IwFH5BvOjB-FsUSRO9DtzWrdsRUUI0EGI04bZ07RpmtDMw_Pt9LYyA3rzssB_N8vVt7_ua974C3HpURXfSVU4qGXMoE8qJuE8dl0UiREbie1YoDkfh4I0-TYJJDYKqF8YW7Ys0b-uPz7bOp7a28utTdKo6sc542DMW4pipOjuwg-l3Q6Lb3y8qotiNl1akDPlOp5zqom1i2exXZHpWaGAa2jbz0B9y-btGciPp9A_hYMUWSXf5VkdQy_Qx7G94CJ7Ac1eXudN76I1dkptmj8JBifu-MMtjc4KUlMistPVWmnAtSa6neWrrtEihSPGNWplrIszkz07hrf_42hs4qx0SHIGJuEQVKVWIHClkBnJFVcB8nrk-R95AhfRUFmbU57GgMuUhFT7yPRVI_06EQpidXs6grgudXQBJpYhiGlEl0xDHoWmAJzjmroC5XHLWgJsKr-RraYSRoIAwACcG4MQC3IBmBWWy-hjmiWdMAlEJ0bgB50tU10NU09EAtoX3-gZjf719BaPC2mCvouDy309ewZ5n1LNdUGlCvZwtsmukGGXawsCasBbs3j-Oxi8tK9TxOKRRywbbD7841zs |
| link.rule.ids | 230,314,727,780,784,864,885,2221,12056,21388,24318,27924,27925,31719,33744,43310,43805,53791,53793,73745,74302 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9tAEB614UB7QC2vpjy6UnvdEtvrXfuE0gBKeUSoAombtd71KuawDsTw-zvjOCEBiattraVvxjvfjGe_AfgVCpf0bOB4bpXiQhnHEx0JHqjESGQkUdgkilcjObwV53fxXVtwm7ZtlfM9sdmobWWoRn4UktIc0mmRHk8eOE2Nor-r7QiNj7BGyulxB9b-nI6u_y2qLOiiYRqkM11SheTnqB776jc5tlyNRG_o5esuyaWwc_YFNlq-yPozA3-FD4XfhM9LKoJbcNH3dckHJ4PrgJV03KPimOTeP1GBbMqQlDJb1E3HlWfaW1b6cZk3nVqscqx6xmxZe2bI_I_bcHt2ejMY8nZGAjcYimvMI62TyJKkItCdcLGKdBFEGpmDMDZ0hSxEpFMjbK6lMBEyPhfbqGekMTTrZQc6vvLFN2C5NUkqEuFsLnEdkcd4QWP0ilWgrVZd-DnHK5vMpDAyTCEI1YxQzRpUu7A_hzJrP4dp9mK8LuzOUF0sQYeIRNzrdUGt4L14gASwV-_4ctwIYZOUPDKW7--_8gesD2-uLrPLv6OLPfgUUsLc1FD2oVM_PhUHyCrq_LB1nf8Y-s5y |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwEB5BKyE4IB67ULYLluBqmodjJydU-lChUFWISr1Fjh2r4eCUNuX3M07SbstKXJPIkb6ZeL6ZjL8B-BAwE3vaNzTTQlAmlKGxDBn1Raw4MpIwqBPF7ws-W7Gv62jd9j_t27bK455Yb9S6VK5GPgic0hzSaZYMTNsWsRxPP21_UzdByv1pbcdpPIQuRkUv6ED382Sx_HGquKC7BomfNBqlAonQoNrY8qNzcn4Zle5RzX87Js9C0PQZPG25Ixk2xn4OD3L7Ap6cKQq-hPnQVgUdjUdLnxTu6EdJMeH9dXDFsj1Bgkp0XtXdV5ZIq0lhN0VWd22R0pDyD2bO0hLlXGF3Bavp5OdoRtt5CVRhWK4wp9SGI2PiwhnAMBOJUOZ-KJFFMKUDk_OchTJRTGeSMxUi-zORDj3FlXJzX66hY0ubvwaSaRUnLGZGZxzXYVmEFyRGskj4UkvRg_dHvNJtI4uRYjrhUE0dqmmNag_6RyjT9tPYp3eG7MGrBtXTEu5AEYs8rwfiAu_TA04M-_KOLTa1KLaTlUf28ub_r3wHj9Br0m9fFvMbeBy43Lkup_ShU-0O-S0SjCp723rOX2CL0p8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Anti-CDCP1+immuno-conjugates+for+detection+and+inhibition+of+ovarian+cancer&rft.jtitle=Theranostics&rft.au=Harrington%2C+Brittney+S&rft.au=He%2C+Yaowu&rft.au=Khan%2C+Tashbib&rft.au=Puttick%2C+Simon&rft.date=2020-01-01&rft.eissn=1838-7640&rft.volume=10&rft.issue=5&rft.spage=2095&rft_id=info:doi/10.7150%2Fthno.30736&rft_id=info%3Apmid%2F32104500&rft.externalDocID=32104500 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1838-7640&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1838-7640&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1838-7640&client=summon |